The Indian pharmaceutical sector witnessed significant developments as major companies announced production updates, regulatory approvals, and fundraising activities that will impact their operations and growth trajectories.

Cipla Halts Key Drug Production

Cipla Ltd announced on Thursday that production of Lanreotide injection, one of its key pharmaceutical products, will be temporarily paused due to operational challenges at its supply partner's facility. The disruption stems from ongoing remediation activities at Pharmathen International S.A.'s manufacturing plant located in Rodopi, Greece.

Lanreotide injection serves as a critical treatment option for hormone-related disorders and is also utilized in cancer tumour treatments. The company stated that re-supply of Lanreotide to the market is expected to resume in the first half of the financial year 2026-27. Until manufacturing operations restart, the product will remain in limited supply, subject to quality clearance requirements.

Zydus Secures FDA Approval for Blood Disorder Treatment

Zydus Lifesciences Ltd achieved a significant regulatory milestone by securing final approval from the US Food and Drug Administration for Eltrombopag Tablets. The approval covers multiple strengths including 12.50 mg, 25.00 mg, 50.00 mg, and 75.00 mg formulations.

The tablets are specifically indicated for treating thrombocytopenia, a condition characterized by low platelet count in specific blood disorders. Production of these tablets will take place at the group's formulation manufacturing facility located at the Special Economic Zone in Ahmedabad.

Biocon Completes Major Fundraising Initiative

Biocon Ltd, the innovation-led global biopharmaceutical company, successfully completed a Qualified Institutions Placement raising ₹4,150.00 crore from eligible qualified institutional buyers. The QIP was priced at ₹368.35 per share and conducted between January 12 and 14.

The QIP attracted strong investor interest from a broad mix of domestic and international participants. The proceeds will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited, including repayment of debt availed in this regard.

These developments highlight the dynamic nature of India's pharmaceutical industry, with companies navigating supply chain challenges while simultaneously pursuing growth opportunities through regulatory approvals and strategic financial initiatives.

Cipla faces a temporary disruption in its lanreotide supply chain following regulatory action by the US Food and Drug Administration. The pharmaceutical giant has announced that production of the drug has been paused due to compliance issues at a key manufacturing facility.

Regulatory Action Details

The USFDA has issued a Form 483 to Pharmathen's manufacturing plant located in Greece. Form 483 is a regulatory document that lists observations of conditions or practices that may violate FDA regulations, typically issued following facility inspections.

Production and Supply Timeline

The regulatory compliance issues have necessitated a temporary halt in lanreotide production at the Greece facility. Cipla has provided guidance on when normal supply operations are expected to resume.

The company anticipates that lanreotide supply will be restored during the first half of FY27, indicating a significant timeline for addressing the regulatory concerns and resuming normal manufacturing operations.

Impact on Operations

This development affects Cipla's lanreotide supply chain, a drug used in various therapeutic applications. The pause in production at Pharmathen's Greece plant represents a notable operational challenge for the pharmaceutical company's product portfolio.

The timeline for supply restoration suggests that resolving the compliance issues identified in the Form 483 will require substantial remedial measures and subsequent regulatory approval before manufacturing can recommence.